Medtronic (NYSE:MDT) today announced a slew of new percutaneous coronary intervention devices it added to its portfolio, including the DxTerity diagnostic angiography catheter line, the DxTerity TRA, InTRAkit transradial devices and the TRAcelet compression device.
The Fridley, Minn.-based company said all of the items have already received FDA clearance in the US and CE Mark approval in the European Union for use in diagnostic cardiac catheterization procedures and percutaneous coronary interventions.
Medtronic’s DxTerity and DxTerity TRA diagnostic catheters are designed to help determine whether revascularization is necessary in coronary artery disease patients.
“The global approval of the DxTerity Diagnostic Catheters, as well as the introduction of the new Medtronic suite of transradial products represents a significant step forward for patients requiring PCI procedures. It’s increasingly important to have a full suite of products accompanied by robust training to increase physician utilization, improve patient comfort and enable same-day discharge,” Dr. Sunil Rao of Duke University said in a prepared statement.
The company said it also launched the Transradial Arc Curriculum training solution in the US, looking to support adoption of the transradial approach.
“Our new line of comprehensive transradial products and programs that support PCI from start to finish were developed to meet the evolving clinical and health economic needs of physicians, administrators and cath lab teams around the globe. Our intent with these recent innovations in our premium product portfolio is to help accelerate adoption of the transradial approach so that more patients and hospitals may experience the advantages transradial access can bring,” coronary and renal denervation biz GM Jason Weidman said in a press release.
Earlier today, Medtronic said it’s launching a outcomes-based training program in Europe, the Middle East & Africa that aims to reach 500,000 healthcare providers over the next 5 years.
It’s part of the push toward “value-based healthcare” for the world’s largest pure-play medical device maker, which chairman & CEO Omar Ishrak has championed for years. The new program, Medtronic Impact, goes beyond traditional training on products and procedures, the company said.